Showing results (321-330 of 335) with videos related to
Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07J Philip Kuebler, H Samuel Wieand, Michael J O'Connell, et al.The New England Journal of Medicine|October 18, 2013
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineDaniel D Von Hoff, Thomas Ervin, Francis P Arena, et al.Investigational New Drugs|February 12, 2013
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignanciesGlen J Weiss, Joseph Chao, Jeffrey D Neidhart, et al.Plos One|October 17, 2012
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencingWinnie S Liang, David W Craig, John Carpten, et al.JCI Insight|February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced CholangiocarcinomaMilind Javle, Maeve Lowery, Rachna T Shroff, et al.Physical Review Letters|January 7, 2021
Results on Low-Mass Weakly Interacting Massive Particles from an 11 kg d Target Exposure of DAMIC at SNOLABA Aguilar-Arevalo, D Amidei, D Baxter, et al.Nature|March 8, 2019
Hepatocytes direct the formation of a pro-metastatic niche in the liverJae W Lee, Meredith L Stone, Paige M Porrett, et al.Physical Review Letters|November 26, 2019
Constraints on Light Dark Matter Particles Interacting with Electrons from DAMIC at SNOLABA Aguilar-Arevalo, D Amidei, D Baxter, et al.European Journal of Cancer (Oxford, England : 1990)|July 19, 2015
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapiesVincent J Picozzi, Ramesh K Ramanathan, Maeve A Lowery, et al.Pageof 34